I have a hard time listening to Washington politicians these days. All I hear is obfuscation and finger-pointing. Nothing seems to get done. And while the finger-pointing seems worse than ever, the inability to get anything done is par for the course.
If neither Congress nor the President can provide results, how can we get this country back on track?
Please consider the below amicus request for support overturning an important section 101 decision at the Federal Circuit and thereby providing consistent guidance on what types of inventions are “abstract.”
Evolutionary Intelligence will be filing a combined petition for rehearing and rehearing en banc at the Federal Circuit on April 19, 2017. Amicus support would be due by May 3, 2017.
Here come the biosimilars. Last month, Sandoz, a subsidiary of Swiss multinational pharmaceutical company Novartis, launched Zarxio, the first U.S.-approved biosimilar to be introduced under the Biologics Price Competition and Innovation Act.
BPCIA, as the reader likely knows, created a pathway to regulatory approval of a competitive biologic, analogous to what Hatch-Waxman did with the accelerated new drug application (ANDA) route for generic pharmaceuticals in 1984.
If you’re an innovation buff, and I am, the Internet of Things is thrilling. That is, when it’s not a little creepy.
If you’re a football fan (and I am), learning that this season in the National Football League, worn sensors will connect players’ movements on the field to a computer for the purpose of data analysis seems kind of fun—although, outside the sports arena and taken to an extreme, this type of tracking could get really creepy. (More on that in a minute.)
ABC’s Shark Tank has become my favorite show. I guess you could have predicted that. Every Friday night, my girls and I settle down on the couch to get our fix. Bring on the munchies!
Did anyone catch last week’s episode (EP605), apparently a rerun from 17 October 2014? In the first presentation, the contestants presented an inner-tube with metal bars in the middle to support safe jumping. Called the Jungle Jumparoo.
IBM is leading the pack in developing cloud patents, according to a recent piece in Computerworld. But is the outlook sunny?
IBM is touting its fat IP portfolio, indeed. That’s (count ‘em) 7,534 patents in 2014 alone. Microsoft won 2,829 in the same period, Amazon 745. But IBM is getting flattened in the market right now, after being a market darling between about 2004 and 2011 or so.
Alice is in line to get a look in the Supreme Court’s mirror. What will she see?
Long-time commentator Lyle Denniston has just published a short piece on SCOTUSblog.com about what promises to be a critically important patent ruling at the Supreme Court, in Alice Corporation v. CLS Bank International.
